Drug Name Inderal

Flomax, Alna, Josir, Pradif, Secotex, Urolosin, Mecir (tamsulosin). Indicated for the treatment of Lower urinary tract Symptoms (LUTS) associated with benign prostate hyperplasia and available since 1996 as capsule controlled release formulation in the main world markets. Starting in 2005, a new tablet formulation based on the OCAS (Oral Controlled Absorption System) technology has been made available in many European markets and in Canada.
Because of Accutane's teratogenicity and to minimize fetal exposure, Accutane is approved for marketing only under a special restricted distribution program approved by the Food and Drug Administration. Accutane must only be prescribed by prescribers who are registered and activated with the iPLEDGE program. Accutane must only be dispensed by a pharmacy registered and activated with iPLEDGE, and must only be dispensed to patients who are registered and meet all the requirements.

 

In Europe, it was indicated for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2, or patients with a BMI greater than 27 kg/m2 with associated risk factors, such as type 2 diabetes or dyslipidaemia. In the UK, it was available beginning in July 2006. As of 2008, the drug was available in 56 countries.
Dr. Rhee and colleagues compared the identification of prediabetes, dysglycemia (diabetes or prediabetes), and diabetes by the recommended HbA1c-based screening with the conventional oral glucose tolerance test (OGTT).